{"id":5988,"date":"2022-10-25T02:15:21","date_gmt":"2022-10-25T02:15:21","guid":{"rendered":"\/\/smallcapscn.x5view.co\/?p=5988"},"modified":"2023-08-29T17:56:00","modified_gmt":"2023-08-29T17:56:00","slug":"prescient-therapeutics-positive-safety-data-ptx-100-study-t-cell-lymphoma-patients","status":"publish","type":"post","link":"https:\/\/smallcapscn.x5view.co\/?p=5988","title":{"rendered":"Prescient Therapeutics \u62a5\u544a\u4e86 PTX-100 \u5bf9 T \u7ec6\u80de\u6dcb\u5df4\u7624\u60a3\u8005\u7684\u7814\u7a76\u7684\u79ef\u6781\u5b89\u5168\u6027\u6570\u636e"},"content":{"rendered":"<p>Prescient Therapeutics (ASX: PTX) \u5bf9\u5148\u5bfc\u836f\u7269 PTX-100 \u5bf9\u590d\u53d1\u6027\u548c\u96be\u6cbb\u6027 T \u7ec6\u80de\u6dcb\u5df4\u7624 (TCL) \u7684\u5f71\u54cd\u8fdb\u884c\u7684\u4e00\u9879\u7814\u7a76\u5728\u96be\u4ee5\u6cbb\u7597\u7684\u60a3\u8005\u7fa4\u4f53\u4e2d\u7ee7\u7eed\u663e\u793a\u51fa\u4ee4\u4eba\u9f13\u821e\u7684\u4e34\u5e8a\u6d3b\u6027\u3002<\/p>\n<p>\u8be5\u7814\u7a76\u5305\u62ec\u4e00\u4e2a\u6269\u5c55\u961f\u5217\uff0c\u5e76\u5728\u8840\u6db2\u5b66\u5bb6 H Miles Prince \u6559\u6388\u7684\u9886\u5bfc\u4e0b\u5728\u58a8\u5c14\u672c\u7684 Epworth Hospital \u8fdb\u884c\u3002<\/p>\n<p>\u6269\u5c55\u961f\u5217\u5305\u62ec 12 \u540d\u60a3\u8005\uff0c\u5176\u4e2d 7 \u4eba\u8fc4\u4eca\u5df2\u670d\u7528 PTX-100\u3002<\/p>\n<p>\u56db\u540d\u60a3\u8005\u60a3\u6709\u5916\u5468 T \u7ec6\u80de\u6dcb\u5df4\u7624 (PTCL)\uff0c\u4e09\u540d\u60a3\u8005\u60a3\u6709\u76ae\u80a4 T \u7ec6\u80de\u6dcb\u5df4\u7624 (CTCL)\u3002<\/p>\n<p>\u60a3\u8005\u63a5\u53d7\u4e86\u4e2d\u4f4d\u6570\u7684\u56db\u79cd\u5148\u524d\u6cbb\u7597\u7ebf\u548c\u591a\u8fbe\u516d\u79cd\u5148\u524d\u6cbb\u7597\u7ebf\u6765\u6cbb\u7597\u4ed6\u4eec\u7684\u6dcb\u5df4\u7624\u3002<\/p>\n<p>PTX-100 \u7684\u6700\u9ad8\u5242\u91cf\u4e3a\u6bcf\u7acb\u65b9\u7c73\u4f53\u8868 2,000 \u6beb\u514b\u3002<\/p>\n<h2>\u5b89\u5168\u7b80\u4ecb<\/h2>\n<p>Prescient \u8bf4 PTX-100 \u8868\u73b0\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\uff0c\u4e0d\u826f\u4e8b\u4ef6\u5f88\u5c11\uff0c\u8fc4\u4eca\u4e3a\u6b62\u6ca1\u6709\u4e25\u91cd\u7684\u4e8b\u4ef6\u62a5\u9053\u3002<\/p>\n<p>\u4e24\u540d\u5f00\u59cb\u6cbb\u7597\u7684 PTCL \u60a3\u8005\u56e0\u4e0e\u8bd5\u9a8c\u65e0\u5173\u7684\u539f\u56e0\u9000\u51fa\u4e86\u7814\u7a76\u3002<\/p>\n<p>\u53e6\u4e00\u540d PTCL \u60a3\u8005\u56e0\u4e0e\u7814\u7a76\u65e0\u5173\u7684\u539f\u56e0\u53bb\u4e16\u3002<\/p>\n<p>\u636e\u62a5\u9053\uff0c\u6b64\u7c7b\u4e8b\u4ef6\u5728\u665a\u671f\u6076\u6027\u80bf\u7624\u7684\u7814\u7a76\u4e2d\u7ecf\u5e38\u53d1\u751f\u3002<\/p>\n<p>Prescient \u8bf4\uff0c\u867d\u7136\u6240\u6709\u4e09\u540d\u60a3\u8005\u90fd\u6ca1\u6709\u8db3\u591f\u957f\u7684\u65f6\u95f4\u53c2\u4e0e\u7814\u7a76\u4ee5\u89c2\u5bdf\u53cd\u5e94\uff0c\u4f46\u4ecd\u6536\u96c6\u4e86\u76f8\u5173\u7684\u836f\u4ee3\u52a8\u529b\u5b66\u548c\u5b89\u5168\u6027\u6570\u636e\u3002<\/p>\n<p>\u56db\u540d\u60a3\u8005\u4ecd\u5728\u63a5\u53d7\u6cbb\u7597\uff0c\u6b63\u5728\u62db\u52df\u5176\u4ed6\u60a3\u8005\u3002<\/p>\n<p>\u8be5\u516c\u53f8\u8868\u793a\uff0c\u8be5\u7814\u7a76\u5c06\u7ee7\u7eed\u5f00\u653e\uff0c\u540c\u65f6\u60a3\u8005\u7ee7\u7eed\u4ece PTX-100\u4e2d\u83b7\u5f97\u4e34\u5e8a\u76ca\u5904\u3002<\/p>\n<h2>\u4ee4\u4eba\u5370\u8c61\u6df1\u523b\u7684\u56de\u5e94<\/h2>\n<p>Prescient \u9996\u5e2d\u6267\u884c\u5b98\u517c\u8463\u4e8b\u603b\u7ecf\u7406 Steven Yatomi-Clarke \u8868\u793a\uff0c\u8be5\u7814\u7a76\u7ee7\u7eed\u5728\u5168\u8eab\u548c\u76ae\u80a4 TCL \u4e2d\u4ea7\u751f\u4ee4\u4eba\u5370\u8c61\u6df1\u523b\u7684\u53cd\u5e94\u3002<\/p>\n<p>\u4ed6\u8bf4\uff1a\u201c\u770b\u5230 PTX-100 \u5728\u4f17\u6240\u5468\u77e5\u96be\u4ee5\u6cbb\u7597\u7684\u60a3\u8005\u7fa4\u4f53\u4e2d\u663e\u793a\u51fa\u4e34\u5e8a\u6d3b\u6027\u662f\u975e\u5e38\u4ee4\u4eba\u5174\u594b\u7684\uff0c\u800c\u4e14\u8fd9\u4e9b\u60a3\u8005\u4e4b\u524d\u7684\u51e0\u6761\u6cbb\u7597\u65b9\u6cd5\u90fd\u5931\u8d25\u4e86\u3002\u201d<\/p>\n<p>\u201c PTX-100 \u7ee7\u7eed\u8868\u73b0\u51fa\u51fa\u8272\u7684\u5b89\u5168\u6027\uff0c\u8fd9\u4e0e\u73b0\u6709\u7684 TCL \u7597\u6cd5\u4e0d\u540c\u2026\u2026\u770b\u5230 CTCL \u60a3\u8005\u7684\u4ee4\u4eba\u9f13\u821e\u7684\u53cd\u5e94\u4ee4\u4eba\u5174\u594b\uff0c\u6211\u4eec\u7684\u76ee\u6807\u662f\u968f\u7740\u65f6\u95f4\u7684\u63a8\u79fb\u62db\u52df\u66f4\u591a\u7684\u60a3\u8005\u3002\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Prescient Therapeutics (ASX: PTX) \u5bf9\u5148\u5bfc\u836f\u7269 PTX-100 \u5bf9\u590d\u53d1\u6027\u548c\u96be\u6cbb\u6027 T \u7ec6\u80de\u6dcb\u5df4\u7624 (TCL) \u7684\u5f71\u54cd\u8fdb\u884c\u7684\u4e00\u9879\u7814\u7a76\u5728\u96be\u4ee5\u6cbb\u7597\u7684\u60a3\u8005\u7fa4\u4f53\u4e2d\u7ee7\u7eed\u663e\u793a\u51fa\u4ee4\u4eba\u9f13\u821e\u7684\u4e34\u5e8a\u6d3b\u6027\u3002 \u8be5\u7814\u7a76\u5305\u62ec\u4e00\u4e2a\u6269\u5c55\u961f\u5217\uff0c\u5e76\u5728\u8840\u6db2\u5b66\u5bb6 H Miles Prince \u6559\u6388\u7684\u9886\u5bfc\u4e0b\u5728\u58a8\u5c14\u672c\u7684 Epworth Hospital \u8fdb\u884c\u3002 \u6269\u5c55\u961f\u5217\u5305\u62ec 12 \u540d\u60a3\u8005\uff0c\u5176\u4e2d 7 \u4eba\u8fc4\u4eca\u5df2\u670d\u7528 PTX-100\u3002 \u56db\u540d\u60a3\u8005\u60a3\u6709\u5916\u5468 T \u7ec6\u80de\u6dcb\u5df4\u7624 (PTCL)\uff0c\u4e09\u540d\u60a3\u8005\u60a3\u6709\u76ae\u80a4 T \u7ec6\u80de\u6dcb\u5df4\u7624 (CTCL)\u3002 \u60a3\u8005\u63a5\u53d7\u4e86\u4e2d\u4f4d\u6570\u7684\u56db\u79cd\u5148\u524d\u6cbb\u7597\u7ebf\u548c\u591a\u8fbe\u516d\u79cd\u5148\u524d\u6cbb\u7597\u7ebf\u6765\u6cbb\u7597\u4ed6\u4eec\u7684\u6dcb\u5df4\u7624\u3002 PTX-100 \u7684\u6700\u9ad8\u5242\u91cf\u4e3a\u6bcf\u7acb\u65b9\u7c73\u4f53\u8868 2,000 \u6beb\u514b\u3002 \u5b89\u5168\u7b80\u4ecb Prescient \u8bf4 PTX-100 \u8868\u73b0\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\uff0c\u4e0d\u826f\u4e8b\u4ef6\u5f88\u5c11\uff0c\u8fc4\u4eca\u4e3a\u6b62\u6ca1\u6709\u4e25\u91cd\u7684\u4e8b\u4ef6\u62a5\u9053\u3002 \u4e24\u540d\u5f00\u59cb\u6cbb\u7597\u7684 PTCL \u60a3\u8005\u56e0\u4e0e\u8bd5\u9a8c\u65e0\u5173\u7684\u539f\u56e0\u9000\u51fa\u4e86\u7814\u7a76\u3002 \u53e6\u4e00\u540d PTCL \u60a3\u8005\u56e0\u4e0e\u7814\u7a76\u65e0\u5173\u7684\u539f\u56e0\u53bb\u4e16\u3002 \u636e\u62a5\u9053\uff0c\u6b64\u7c7b\u4e8b\u4ef6\u5728\u665a\u671f\u6076\u6027\u80bf\u7624\u7684\u7814\u7a76\u4e2d\u7ecf\u5e38\u53d1\u751f\u3002 Prescient \u8bf4\uff0c\u867d\u7136\u6240\u6709\u4e09\u540d\u60a3\u8005\u90fd\u6ca1\u6709\u8db3\u591f\u957f\u7684\u65f6\u95f4\u53c2\u4e0e\u7814\u7a76\u4ee5\u89c2\u5bdf\u53cd\u5e94\uff0c\u4f46\u4ecd\u6536\u96c6\u4e86\u76f8\u5173\u7684\u836f\u4ee3\u52a8\u529b\u5b66\u548c\u5b89\u5168\u6027\u6570\u636e\u3002 \u56db\u540d\u60a3\u8005\u4ecd\u5728\u63a5\u53d7\u6cbb\u7597\uff0c\u6b63\u5728\u62db\u52df\u5176\u4ed6\u60a3\u8005\u3002 \u8be5\u516c\u53f8\u8868\u793a\uff0c\u8be5\u7814\u7a76\u5c06\u7ee7\u7eed\u5f00\u653e\uff0c\u540c\u65f6\u60a3\u8005\u7ee7\u7eed\u4ece PTX-100\u4e2d\u83b7\u5f97\u4e34\u5e8a\u76ca\u5904\u3002 \u4ee4\u4eba\u5370\u8c61\u6df1\u523b\u7684\u56de\u5e94&hellip; <a class=\"more-link\" href=\"https:\/\/smallcapscn.x5view.co\/?p=5988\">Continue reading <span class=\"screen-reader-text\">Prescient Therapeutics \u62a5\u544a\u4e86 PTX-100 \u5bf9 T \u7ec6\u80de\u6dcb\u5df4\u7624\u60a3\u8005\u7684\u7814\u7a76\u7684\u79ef\u6781\u5b89\u5168\u6027\u6570\u636e<\/span><\/a><\/p>\n","protected":false},"author":4,"featured_media":18885,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[171],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v17.3 (Yoast SEO v21.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Prescient Therapeutics \u62a5\u544a\u4e86 PTX-100 \u5bf9 T \u7ec6\u80de\u6dcb\u5df4\u7624\u60a3\u8005\u7684\u7814\u7a76\u7684\u79ef\u6781\u5b89\u5168\u6027\u6570\u636e<\/title>\n<meta name=\"description\" content=\"Prescient Therapeutics (ASX: PTX) \u5bf9\u5148\u5bfc\u836f\u7269 PTX-100 \u5bf9\u590d\u53d1\u6027\u548c\u96be\u6cbb\u6027 T \u7ec6\u80de\u6dcb\u5df4\u7624 (TCL) \u7684\u5f71\u54cd\u8fdb\u884c\u7684\u4e00\u9879\u7814\u7a76\u5728\u96be\u4ee5\u6cbb\u7597\u7684\u60a3\u8005\u7fa4\u4f53\u4e2d\u7ee7\u7eed\u663e\u793a\u51fa\u4ee4\u4eba\u9f13\u821e\u7684\u4e34\u5e8a\u6d3b\u6027\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prescient Therapeutics \u62a5\u544a\u4e86 PTX-100 \u5bf9 T \u7ec6\u80de\u6dcb\u5df4\u7624\u60a3\u8005\u7684\u7814\u7a76\u7684\u79ef\u6781\u5b89\u5168\u6027\u6570\u636e\" \/>\n<meta property=\"og:description\" content=\"Prescient Therapeutics (ASX: PTX) \u5bf9\u5148\u5bfc\u836f\u7269 PTX-100 \u5bf9\u590d\u53d1\u6027\u548c\u96be\u6cbb\u6027 T \u7ec6\u80de\u6dcb\u5df4\u7624 (TCL) \u7684\u5f71\u54cd\u8fdb\u884c\u7684\u4e00\u9879\u7814\u7a76\u5728\u96be\u4ee5\u6cbb\u7597\u7684\u60a3\u8005\u7fa4\u4f53\u4e2d\u7ee7\u7eed\u663e\u793a\u51fa\u4ee4\u4eba\u9f13\u821e\u7684\u4e34\u5e8a\u6d3b\u6027\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-positive-safety-data-ptx-100-study-t-cell-lymphoma-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-25T02:15:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T17:56:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Prescient-Therapeutics-ASX-PTX-PTX-100-trial-Professor-H.-Miles-Prince-Epworth-Hospital-Melbourne.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Imelda Cotton\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Imelda Cotton\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-positive-safety-data-ptx-100-study-t-cell-lymphoma-patients\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-positive-safety-data-ptx-100-study-t-cell-lymphoma-patients\/\",\"name\":\"Prescient Therapeutics \u62a5\u544a\u4e86 PTX-100 \u5bf9 T \u7ec6\u80de\u6dcb\u5df4\u7624\u60a3\u8005\u7684\u7814\u7a76\u7684\u79ef\u6781\u5b89\u5168\u6027\u6570\u636e\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2022-10-25T02:15:21+00:00\",\"dateModified\":\"2023-08-29T17:56:00+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e\"},\"description\":\"Prescient Therapeutics (ASX: PTX) \u5bf9\u5148\u5bfc\u836f\u7269 PTX-100 \u5bf9\u590d\u53d1\u6027\u548c\u96be\u6cbb\u6027 T \u7ec6\u80de\u6dcb\u5df4\u7624 (TCL) \u7684\u5f71\u54cd\u8fdb\u884c\u7684\u4e00\u9879\u7814\u7a76\u5728\u96be\u4ee5\u6cbb\u7597\u7684\u60a3\u8005\u7fa4\u4f53\u4e2d\u7ee7\u7eed\u663e\u793a\u51fa\u4ee4\u4eba\u9f13\u821e\u7684\u4e34\u5e8a\u6d3b\u6027\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-positive-safety-data-ptx-100-study-t-cell-lymphoma-patients\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-positive-safety-data-ptx-100-study-t-cell-lymphoma-patients\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-positive-safety-data-ptx-100-study-t-cell-lymphoma-patients\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prescient Therapeutics \u62a5\u544a\u4e86 PTX-100 \u5bf9 T \u7ec6\u80de\u6dcb\u5df4\u7624\u60a3\u8005\u7684\u7814\u7a76\u7684\u79ef\u6781\u5b89\u5168\u6027\u6570\u636e\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e\",\"name\":\"Imelda Cotton\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g\",\"caption\":\"Imelda Cotton\"},\"description\":\"Imelda Cotton has over 20 years experience as a journalist and communications professional. She has spent the bulk of her career in the resources sector, having also worked directly with oil and gas majors and as a journalist covering a vast array of ASX listed companies within the resources, energy, science and health sectors.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=4\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Prescient Therapeutics \u62a5\u544a\u4e86 PTX-100 \u5bf9 T \u7ec6\u80de\u6dcb\u5df4\u7624\u60a3\u8005\u7684\u7814\u7a76\u7684\u79ef\u6781\u5b89\u5168\u6027\u6570\u636e","description":"Prescient Therapeutics (ASX: PTX) \u5bf9\u5148\u5bfc\u836f\u7269 PTX-100 \u5bf9\u590d\u53d1\u6027\u548c\u96be\u6cbb\u6027 T \u7ec6\u80de\u6dcb\u5df4\u7624 (TCL) \u7684\u5f71\u54cd\u8fdb\u884c\u7684\u4e00\u9879\u7814\u7a76\u5728\u96be\u4ee5\u6cbb\u7597\u7684\u60a3\u8005\u7fa4\u4f53\u4e2d\u7ee7\u7eed\u663e\u793a\u51fa\u4ee4\u4eba\u9f13\u821e\u7684\u4e34\u5e8a\u6d3b\u6027\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Prescient Therapeutics \u62a5\u544a\u4e86 PTX-100 \u5bf9 T \u7ec6\u80de\u6dcb\u5df4\u7624\u60a3\u8005\u7684\u7814\u7a76\u7684\u79ef\u6781\u5b89\u5168\u6027\u6570\u636e","og_description":"Prescient Therapeutics (ASX: PTX) \u5bf9\u5148\u5bfc\u836f\u7269 PTX-100 \u5bf9\u590d\u53d1\u6027\u548c\u96be\u6cbb\u6027 T \u7ec6\u80de\u6dcb\u5df4\u7624 (TCL) \u7684\u5f71\u54cd\u8fdb\u884c\u7684\u4e00\u9879\u7814\u7a76\u5728\u96be\u4ee5\u6cbb\u7597\u7684\u60a3\u8005\u7fa4\u4f53\u4e2d\u7ee7\u7eed\u663e\u793a\u51fa\u4ee4\u4eba\u9f13\u821e\u7684\u4e34\u5e8a\u6d3b\u6027\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-positive-safety-data-ptx-100-study-t-cell-lymphoma-patients\/","og_site_name":"smallcapsCN","article_published_time":"2022-10-25T02:15:21+00:00","article_modified_time":"2023-08-29T17:56:00+00:00","og_image":[{"width":640,"height":400,"url":"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Prescient-Therapeutics-ASX-PTX-PTX-100-trial-Professor-H.-Miles-Prince-Epworth-Hospital-Melbourne.jpg","type":"image\/jpeg"}],"author":"Imelda Cotton","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Imelda Cotton"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-positive-safety-data-ptx-100-study-t-cell-lymphoma-patients\/","url":"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-positive-safety-data-ptx-100-study-t-cell-lymphoma-patients\/","name":"Prescient Therapeutics \u62a5\u544a\u4e86 PTX-100 \u5bf9 T \u7ec6\u80de\u6dcb\u5df4\u7624\u60a3\u8005\u7684\u7814\u7a76\u7684\u79ef\u6781\u5b89\u5168\u6027\u6570\u636e","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2022-10-25T02:15:21+00:00","dateModified":"2023-08-29T17:56:00+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e"},"description":"Prescient Therapeutics (ASX: PTX) \u5bf9\u5148\u5bfc\u836f\u7269 PTX-100 \u5bf9\u590d\u53d1\u6027\u548c\u96be\u6cbb\u6027 T \u7ec6\u80de\u6dcb\u5df4\u7624 (TCL) \u7684\u5f71\u54cd\u8fdb\u884c\u7684\u4e00\u9879\u7814\u7a76\u5728\u96be\u4ee5\u6cbb\u7597\u7684\u60a3\u8005\u7fa4\u4f53\u4e2d\u7ee7\u7eed\u663e\u793a\u51fa\u4ee4\u4eba\u9f13\u821e\u7684\u4e34\u5e8a\u6d3b\u6027\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-positive-safety-data-ptx-100-study-t-cell-lymphoma-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-positive-safety-data-ptx-100-study-t-cell-lymphoma-patients\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-positive-safety-data-ptx-100-study-t-cell-lymphoma-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"Prescient Therapeutics \u62a5\u544a\u4e86 PTX-100 \u5bf9 T \u7ec6\u80de\u6dcb\u5df4\u7624\u60a3\u8005\u7684\u7814\u7a76\u7684\u79ef\u6781\u5b89\u5168\u6027\u6570\u636e"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e","name":"Imelda Cotton","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g","caption":"Imelda Cotton"},"description":"Imelda Cotton has over 20 years experience as a journalist and communications professional. She has spent the bulk of her career in the resources sector, having also worked directly with oil and gas majors and as a journalist covering a vast array of ASX listed companies within the resources, energy, science and health sectors.","url":"https:\/\/smallcapscn.x5view.co\/?author=4"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/5988"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5988"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/5988\/revisions"}],"predecessor-version":[{"id":15867,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/5988\/revisions\/15867"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/18885"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5988"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5988"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5988"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}